Global Biopharmaceutical and Bio-CDMO Market Growth (Status and Outlook) 2024-2030

2024

Global Biopharmaceutical and Bio-CDMO Market Growth (Status and Outlook) 2024-2030

Name: Global Biopharmaceutical and Bio-CDMO Market Growth (Status and Outlook) 2024-2030
Brand: Bonafide Research
SKU: 95001556
Price: 3450 USD
Availability: InStock
Rating: 5 (15.05 reviews)

The global biopharmaceutical and Bio-CDMO (contract development and manufacturing organization) market has witnessed substantial growth due to the increasing demand for biologics a

Bonafide Trust
15-08-2024
Pages : 133
Figures : 76
Tables : 131
Region : Global
Category : Lifescience & Healthcare
Pharmaceutical

Schedule a Call

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

The global biopharmaceutical and biocontract development and manufacturing organization (Bio-CDMO) market has witnessed substantial growth over recent years, spurred by multiple factors that collectively drive demand and innovation in this essential industry. The biopharmaceutical sector itself is experiencing remarkable expansion due to advancements in biotechnologies, an increased prevalence of chronic diseases, and the growing demand for personalized medicines and advanced therapies. Specifically, biologics, including monoclonal antibodies, recombinant proteins, and gene therapies, are frontrunners in this growth due to their revolutionary role in treating previously untreatable conditions. These advancements have created a rising need for specialized Bio-CDMOs equipped with state-of-the-art technology and expertise in handling complex biologic substances. According to recent reports, the pharmaceutical CDMO market size was valued at approximately USD 146.0 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.2% from 2024 to 20342. This growth is further fueled by increasing R&D investments, the burgeoning market for biosimilars, and the ever-evolving regulatory landscape that demands high-quality and compliant production processes. Major players in the Bio-CDMO market, such as Lonza and Samsung Biologics, are significantly investing in expanding their capabilities and service offerings to meet this rising demand. Additionally, the increasing trend of outsourcing drug development and manufacturing processes among small and medium-sized biotech firms enhances the market's growth dynamics. This outsourcing not only reduces operational costs but also accelerates time-to-market for various therapies and drugs. The integration of artificial intelligence and machine learning in biopharmaceutical production processes also boosts efficiency and innovation, allowing for more precise and scalable manufacturing solutions. Geographically, regions like North America and Europe continue to dominate the market due to their advanced healthcare infrastructure and substantial investments in biotechnology. However, the Asia-Pacific region is rapidly emerging as a significant market player, driven by supportive government policies, growing biotech ecosystems, and increasing collaborations between local CDMOs and global pharmaceutical companies.

The global Biopharmaceutical and Bio-CDMO market size is projected to grow from US$ 28120 million in 2024 to US$ 60540 million in 2030; it is expected to grow at a CAGR of 13.6% from 2024 to 2030. LPI (LP Information)' newest research report, the “Biopharmaceutical and Bio-CDMO Industry Forecast” looks at past sales and reviews total world Biopharmaceutical and Bio-CDMO sales in 2022, providing a comprehensive analysis by region and market sector of projected Biopharmaceutical and Bio-CDMO sales for 2023 through 2029. With Biopharmaceutical and Bio-CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biopharmaceutical and Bio-CDMO industry. This Insight Report provides a comprehensive analysis of the global Biopharmaceutical and Bio-CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Biopharmaceutical and Bio-CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biopharmaceutical and Bio-CDMO market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biopharmaceutical and Bio-CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biopharmaceutical and Bio-CDMO.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample

The global biopharmaceutical and Bio-CDMO market is segmented by type into mammalian and non-mammalian (microbial) production systems, biologics, and biosimilars, each contributing to overall market growth and diversification. Mammalian production systems hold a substantial market share due to their widespread use in producing complex proteins and biologics, such as monoclonal antibodies and recombinant proteins, favored for their ability to closely mimic human biological processes. Non-mammalian or microbial production systems are crucial for producing smaller and less complex therapeutic proteins and enzymes, offering advantages like shorter production times and lower costs ideal for large-scale industrial production. The biologics segment encompasses monoclonal antibodies, recombinant proteins, gene therapies, and vaccines, pivotal in treating various chronic and rare diseases, driven by advancements in biotechnology, the increasing prevalence of chronic diseases, and the rising demand for personalized medicine. Biosimilars represent a rapidly growing segment due to their cost-effectiveness and the patent expirations of several major biologics, expected to witness substantial growth as healthcare systems globally seek affordable alternatives to high-cost biologics. Influenced by technological advancements, increasing R&D investments, and evolving regulatory landscapes, the market growth by type is driven by continuous innovation in production technologies and the rising demand for high-quality, efficient, and cost-effective therapeutics, with various types of production systems and therapeutic products playing a crucial role in meeting the diverse needs of the global healthcare sector.

The global biopharmaceutical and bio-CDMO market is segmented by application into diverse categories that significantly influence market growth and dynamics. Key segments by application include oncology, infectious diseases, neurological disorders, and other therapeutic areas3. Oncology represents a major segment, driven by the increasing prevalence of cancer and the demand for innovative cancer therapies. Biopharmaceutical companies focus on developing advanced therapeutics, including monoclonal antibodies, gene therapies, and personalized medicine, to address the growing need for effective cancer treatments. The infectious diseases segment is also significant, with biopharmaceuticals playing a crucial role in developing vaccines, antiviral drugs, and monoclonal antibodies to combat various infectious diseases, including COVID-19. The ongoing global efforts to strengthen pandemic preparedness and response further propel this segment. Neurological disorders encompass a range of conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The development of biologics and biosimilars targeting these disorders is driven by the increasing prevalence of neurological conditions and the need for innovative treatments. Other therapeutic areas include autoimmune diseases, cardiovascular diseases, metabolic disorders, and rare diseases. The rising incidence of these conditions, coupled with advancements in biotechnology and increased R&D investments, fuels the growth of these segments. Biopharmaceutical companies and Bio-CDMOs collaborate to develop and manufacture high-quality, efficient, and cost-effective therapeutics to meet the diverse needs of the global healthcare sector. The market growth by application is influenced by technological advancements, evolving regulatory landscapes, and the increasing demand for personalized and advanced therapies. As the biopharmaceutical industry continues to expand, the various application segments will play a crucial role in addressing the complex healthcare challenges worldwide, driving the market forward with innovative solutions.

The global biopharmaceutical and bio-CDMO market showcases varied growth patterns across different regions, each significantly contributing based on regional economic conditions, infrastructural developments, and technological advancements. North America spearheads the market, fueled by extensive infrastructure projects and robust residential and commercial construction sectors, with a strong emphasis on sustainable and durable building materials. The region's advanced healthcare infrastructure and substantial investments in biotechnology further bolster market growth. Europe follows closely, with leading countries like Germany, the UK, and France prioritizing the adoption of pressed slabs in both urban and rural construction projects, emphasizing eco-friendly construction and renovation. The Asia-Pacific region, particularly China and India, represents the rapidly growing segment, driven by accelerated urbanization, population growth, and significant government investments in infrastructure. The rise of the middle class and increasing disposable incomes in these regions also boost the demand for high-quality building materials such as pressed slabs. In Latin America, moderate growth is observed, with countries like Brazil and Mexico being key contributors propelled by infrastructural developments and residential construction. The Middle East and Africa (MEA) region is witnessing significant growth primarily due to large-scale infrastructure projects and an increasing focus on tourism and hospitality sectors. Countries like the UAE and Saudi Arabia are heavily investing in infrastructure, pushing the demand for durable and versatile pressed slabs. Innovations in manufacturing technologies and a growing awareness of sustainable building practices across all these regions are anticipated to drive the market forward, catering to the diverse needs of the construction industry globally.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Research Analyst

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Biopharmaceutical and Bio-CDMO Market Size 2019-2030
2.1.2 Biopharmaceutical and Bio-CDMO Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Biopharmaceutical and Bio-CDMO by Country/Region, 2019, 2023 & 2030
2.2 Biopharmaceutical and Bio-CDMO Segment by Type
2.2.1 Cell and Gene Therapies
2.2.2 Antibodies
2.2.3 Vaccines
2.2.4 Other
2.3 Biopharmaceutical and Bio-CDMO Market Size by Type
2.3.1 Biopharmaceutical and Bio-CDMO Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Biopharmaceutical and Bio-CDMO Market Size Market Share by Type (2019-2024)
2.4 Biopharmaceutical and Bio-CDMO Segment by Application
2.4.1 SMBs
2.4.2 Large Companies
2.5 Biopharmaceutical and Bio-CDMO Market Size by Application
2.5.1 Biopharmaceutical and Bio-CDMO Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Biopharmaceutical and Bio-CDMO Market Size Market Share by Application (2019-2024)
3 Biopharmaceutical and Bio-CDMO Market Size by Player
3.1 Biopharmaceutical and Bio-CDMO Market Size Market Share by Player
3.1.1 Global Biopharmaceutical and Bio-CDMO Revenue by Player (2019-2024)
3.1.2 Global Biopharmaceutical and Bio-CDMO Revenue Market Share by Player (2019-2024)
3.2 Global Biopharmaceutical and Bio-CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Biopharmaceutical and Bio-CDMO by Region
4.1 Biopharmaceutical and Bio-CDMO Market Size by Region (2019-2024)
4.2 Global Biopharmaceutical and Bio-CDMO Annual Revenue by Country/Region (2019-2024)
4.3 Americas Biopharmaceutical and Bio-CDMO Market Size Growth (2019-2024)
4.4 APAC Biopharmaceutical and Bio-CDMO Market Size Growth (2019-2024)
4.5 Europe Biopharmaceutical and Bio-CDMO Market Size Growth (2019-2024)
4.6 Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size Growth (2019-2024)
5 Americas
5.1 Americas Biopharmaceutical and Bio-CDMO Market Size by Country (2019-2024)
5.2 Americas Biopharmaceutical and Bio-CDMO Market Size by Type (2019-2024)
5.3 Americas Biopharmaceutical and Bio-CDMO Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biopharmaceutical and Bio-CDMO Market Size by Region (2019-2024)
6.2 APAC Biopharmaceutical and Bio-CDMO Market Size by Type (2019-2024)
6.3 APAC Biopharmaceutical and Bio-CDMO Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Biopharmaceutical and Bio-CDMO Market Size by Country (2019-2024)
7.2 Europe Biopharmaceutical and Bio-CDMO Market Size by Type (2019-2024)
7.3 Europe Biopharmaceutical and Bio-CDMO Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Biopharmaceutical and Bio-CDMO by Region (2019-2024)
8.2 Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size by Type (2019-2024)
8.3 Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Biopharmaceutical and Bio-CDMO Market Forecast
10.1 Global Biopharmaceutical and Bio-CDMO Forecast by Region (2025-2030)
10.1.1 Global Biopharmaceutical and Bio-CDMO Forecast by Region (2025-2030)
10.1.2 Americas Biopharmaceutical and Bio-CDMO Forecast
10.1.3 APAC Biopharmaceutical and Bio-CDMO Forecast
10.1.4 Europe Biopharmaceutical and Bio-CDMO Forecast
10.1.5 Middle East & Africa Biopharmaceutical and Bio-CDMO Forecast
10.2 Americas Biopharmaceutical and Bio-CDMO Forecast by Country (2025-2030)
10.2.1 United States Market Biopharmaceutical and Bio-CDMO Forecast
10.2.2 Canada Market Biopharmaceutical and Bio-CDMO Forecast
10.2.3 Mexico Market Biopharmaceutical and Bio-CDMO Forecast
10.2.4 Brazil Market Biopharmaceutical and Bio-CDMO Forecast
10.3 APAC Biopharmaceutical and Bio-CDMO Forecast by Region (2025-2030)
10.3.1 China Biopharmaceutical and Bio-CDMO Market Forecast
10.3.2 Japan Market Biopharmaceutical and Bio-CDMO Forecast
10.3.3 Korea Market Biopharmaceutical and Bio-CDMO Forecast
10.3.4 Southeast Asia Market Biopharmaceutical and Bio-CDMO Forecast
10.3.5 India Market Biopharmaceutical and Bio-CDMO Forecast
10.3.6 Australia Market Biopharmaceutical and Bio-CDMO Forecast
10.4 Europe Biopharmaceutical and Bio-CDMO Forecast by Country (2025-2030)
10.4.1 Germany Market Biopharmaceutical and Bio-CDMO Forecast
10.4.2 France Market Biopharmaceutical and Bio-CDMO Forecast
10.4.3 UK Market Biopharmaceutical and Bio-CDMO Forecast
10.4.4 Italy Market Biopharmaceutical and Bio-CDMO Forecast
10.4.5 Russia Market Biopharmaceutical and Bio-CDMO Forecast
10.5 Middle East & Africa Biopharmaceutical and Bio-CDMO Forecast by Region (2025-2030)
10.5.1 Egypt Market Biopharmaceutical and Bio-CDMO Forecast
10.5.2 South Africa Market Biopharmaceutical and Bio-CDMO Forecast
10.5.3 Israel Market Biopharmaceutical and Bio-CDMO Forecast
10.5.4 Turkey Market Biopharmaceutical and Bio-CDMO Forecast
10.6 Global Biopharmaceutical and Bio-CDMO Forecast by Type (2025-2030)
10.7 Global Biopharmaceutical and Bio-CDMO Forecast by Application (2025-2030)
10.7.1 GCC Countries Market Biopharmaceutical and Bio-CDMO Forecast
11 Key Players Analysis
11.1 Lonza
11.1.1 Lonza Company Information
11.1.2 Lonza Biopharmaceutical and Bio-CDMO Product Offered
11.1.3 Lonza Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Lonza Main Business Overview
11.1.5 Lonza Latest Developments
11.2 Catalent
11.2.1 Catalent Company Information
11.2.2 Catalent Biopharmaceutical and Bio-CDMO Product Offered
11.2.3 Catalent Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Catalent Main Business Overview
11.2.5 Catalent Latest Developments
11.3 Samsung Biologics
11.3.1 Samsung Biologics Company Information
11.3.2 Samsung Biologics Biopharmaceutical and Bio-CDMO Product Offered
11.3.3 Samsung Biologics Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Samsung Biologics Main Business Overview
11.3.5 Samsung Biologics Latest Developments
11.4 FUJIFILM Diosynth Biotechnologies
11.4.1 FUJIFILM Diosynth Biotechnologies Company Information
11.4.2 FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Product Offered
11.4.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 FUJIFILM Diosynth Biotechnologies Main Business Overview
11.4.5 FUJIFILM Diosynth Biotechnologies Latest Developments
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Information
11.5.2 Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Product Offered
11.5.3 Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Boehringer Ingelheim Main Business Overview
11.5.5 Boehringer Ingelheim Latest Developments
11.6 WuXi AppTech
11.6.1 WuXi AppTech Company Information
11.6.2 WuXi AppTech Biopharmaceutical and Bio-CDMO Product Offered
11.6.3 WuXi AppTech Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 WuXi AppTech Main Business Overview
11.6.5 WuXi AppTech Latest Developments
11.7 Recipharm
11.7.1 Recipharm Company Information
11.7.2 Recipharm Biopharmaceutical and Bio-CDMO Product Offered
11.7.3 Recipharm Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Recipharm Main Business Overview
11.7.5 Recipharm Latest Developments
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Information
11.8.2 Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Product Offered
11.8.3 Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Thermo Fisher Scientific Main Business Overview
11.8.5 Thermo Fisher Scientific Latest Developments
11.9 AGC Biologics
11.9.1 AGC Biologics Company Information
11.9.2 AGC Biologics Biopharmaceutical and Bio-CDMO Product Offered
11.9.3 AGC Biologics Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 AGC Biologics Main Business Overview
11.9.5 AGC Biologics Latest Developments
11.10 Rentschler Biopharma
11.10.1 Rentschler Biopharma Company Information
11.10.2 Rentschler Biopharma Biopharmaceutical and Bio-CDMO Product Offered
11.10.3 Rentschler Biopharma Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Rentschler Biopharma Main Business Overview
11.10.5 Rentschler Biopharma Latest Developments
11.11 KBI Biopharma
11.11.1 KBI Biopharma Company Information
11.11.2 KBI Biopharma Biopharmaceutical and Bio-CDMO Product Offered
11.11.3 KBI Biopharma Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 KBI Biopharma Main Business Overview
11.11.5 KBI Biopharma Latest Developments
11.12 Siegfried
11.12.1 Siegfried Company Information
11.12.2 Siegfried Biopharmaceutical and Bio-CDMO Product Offered
11.12.3 Siegfried Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Siegfried Main Business Overview
11.12.5 Siegfried Latest Developments
11.13 Aenova Group
11.13.1 Aenova Group Company Information
11.13.2 Aenova Group Biopharmaceutical and Bio-CDMO Product Offered
11.13.3 Aenova Group Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Aenova Group Main Business Overview
11.13.5 Aenova Group Latest Developments
11.14 GenScript
11.14.1 GenScript Company Information
11.14.2 GenScript Biopharmaceutical and Bio-CDMO Product Offered
11.14.3 GenScript Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 GenScript Main Business Overview
11.14.5 GenScript Latest Developments
11.15 ProBioGen
11.15.1 ProBioGen Company Information
11.15.2 ProBioGen Biopharmaceutical and Bio-CDMO Product Offered
11.15.3 ProBioGen Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 ProBioGen Main Business Overview
11.15.5 ProBioGen Latest Developments
11.16 Northway Biotech
11.16.1 Northway Biotech Company Information
11.16.2 Northway Biotech Biopharmaceutical and Bio-CDMO Product Offered
11.16.3 Northway Biotech Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Northway Biotech Main Business Overview
11.16.5 Northway Biotech Latest Developments
11.17 3P Biopharmaceuticals
11.17.1 3P Biopharmaceuticals Company Information
11.17.2 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Product Offered
11.17.3 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 3P Biopharmaceuticals Main Business Overview
11.17.5 3P Biopharmaceuticals Latest Developments
12 Research Findings and Conclusion

Table 1. Biopharmaceutical and Bio-CDMO Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ millions)
Table 2. Biopharmaceutical and Bio-CDMO Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Cell and Gene Therapies
Table 4. Major Players of Antibodies
Table 5. Major Players of Vaccines
Table 6. Major Players of Other
Table 7. Biopharmaceutical and Bio-CDMO Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ millions)
Table 8. Global Biopharmaceutical and Bio-CDMO Market Size by Type (2019-2024) & ($ millions)
Table 9. Global Biopharmaceutical and Bio-CDMO Market Size Market Share by Type (2019-2024)
Table 10. Biopharmaceutical and Bio-CDMO Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ millions)
Table 11. Global Biopharmaceutical and Bio-CDMO Market Size by Application (2019-2024) & ($ millions)
Table 12. Global Biopharmaceutical and Bio-CDMO Market Size Market Share by Application (2019-2024)
Table 13. Global Biopharmaceutical and Bio-CDMO Revenue by Player (2019-2024) & ($ millions)
Table 14. Global Biopharmaceutical and Bio-CDMO Revenue Market Share by Player (2019-2024)
Table 15. Biopharmaceutical and Bio-CDMO Key Players Head office and Products Offered
Table 16. Biopharmaceutical and Bio-CDMO Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Biopharmaceutical and Bio-CDMO Market Size by Region (2019-2024) & ($ millions)
Table 20. Global Biopharmaceutical and Bio-CDMO Market Size Market Share by Region (2019-2024)
Table 21. Global Biopharmaceutical and Bio-CDMO Revenue by Country/Region (2019-2024) & ($ millions)
Table 22. Global Biopharmaceutical and Bio-CDMO Revenue Market Share by Country/Region (2019-2024)
Table 23. Americas Biopharmaceutical and Bio-CDMO Market Size by Country (2019-2024) & ($ millions)
Table 24. Americas Biopharmaceutical and Bio-CDMO Market Size Market Share by Country (2019-2024)
Table 25. Americas Biopharmaceutical and Bio-CDMO Market Size by Type (2019-2024) & ($ millions)
Table 26. Americas Biopharmaceutical and Bio-CDMO Market Size Market Share by Type (2019-2024)
Table 27. Americas Biopharmaceutical and Bio-CDMO Market Size by Application (2019-2024) & ($ millions)
Table 28. Americas Biopharmaceutical and Bio-CDMO Market Size Market Share by Application (2019-2024)
Table 29. APAC Biopharmaceutical and Bio-CDMO Market Size by Region (2019-2024) & ($ millions)
Table 30. APAC Biopharmaceutical and Bio-CDMO Market Size Market Share by Region (2019-2024)
Table 31. APAC Biopharmaceutical and Bio-CDMO Market Size by Type (2019-2024) & ($ millions)
Table 32. APAC Biopharmaceutical and Bio-CDMO Market Size by Application (2019-2024) & ($ millions)
Table 33. Europe Biopharmaceutical and Bio-CDMO Market Size by Country (2019-2024) & ($ millions)
Table 34. Europe Biopharmaceutical and Bio-CDMO Market Size Market Share by Country (2019-2024)
Table 35. Europe Biopharmaceutical and Bio-CDMO Market Size by Type (2019-2024) & ($ millions)
Table 36. Europe Biopharmaceutical and Bio-CDMO Market Size by Application (2019-2024) & ($ millions)
Table 37. Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size by Region (2019-2024) & ($ millions)
Table 38. Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size by Type (2019-2024) & ($ millions)
Table 39. Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size by Application (2019-2024) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Biopharmaceutical and Bio-CDMO
Table 41. Key Market Challenges & Risks of Biopharmaceutical and Bio-CDMO
Table 42. Key Industry Trends of Biopharmaceutical and Bio-CDMO
Table 43. Global Biopharmaceutical and Bio-CDMO Market Size Forecast by Region (2025-2030) & ($ millions)
Table 44. Global Biopharmaceutical and Bio-CDMO Market Size Market Share Forecast by Region (2025-2030)
Table 45. Global Biopharmaceutical and Bio-CDMO Market Size Forecast by Type (2025-2030) & ($ millions)
Table 46. Global Biopharmaceutical and Bio-CDMO Market Size Forecast by Application (2025-2030) & ($ millions)
Table 47. Lonza Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 48. Lonza Biopharmaceutical and Bio-CDMO Product Offered
Table 49. Lonza Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 50. Lonza Main Business
Table 51. Lonza Latest Developments
Table 52. Catalent Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 53. Catalent Biopharmaceutical and Bio-CDMO Product Offered
Table 54. Catalent Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 55. Catalent Main Business
Table 56. Catalent Latest Developments
Table 57. Samsung Biologics Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 58. Samsung Biologics Biopharmaceutical and Bio-CDMO Product Offered
Table 59. Samsung Biologics Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 60. Samsung Biologics Main Business
Table 61. Samsung Biologics Latest Developments
Table 62. FUJIFILM Diosynth Biotechnologies Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 63. FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Product Offered
Table 64. FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 65. FUJIFILM Diosynth Biotechnologies Main Business
Table 66. FUJIFILM Diosynth Biotechnologies Latest Developments
Table 67. Boehringer Ingelheim Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 68. Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Product Offered
Table 69. Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 70. Boehringer Ingelheim Main Business
Table 71. Boehringer Ingelheim Latest Developments
Table 72. WuXi AppTech Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 73. WuXi AppTech Biopharmaceutical and Bio-CDMO Product Offered
Table 74. WuXi AppTech Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 75. WuXi AppTech Main Business
Table 76. WuXi AppTech Latest Developments
Table 77. Recipharm Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 78. Recipharm Biopharmaceutical and Bio-CDMO Product Offered
Table 79. Recipharm Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 80. Recipharm Main Business
Table 81. Recipharm Latest Developments
Table 82. Thermo Fisher Scientific Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 83. Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Product Offered
Table 84. Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 85. Thermo Fisher Scientific Main Business
Table 86. Thermo Fisher Scientific Latest Developments
Table 87. AGC Biologics Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 88. AGC Biologics Biopharmaceutical and Bio-CDMO Product Offered
Table 89. AGC Biologics Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 90. AGC Biologics Main Business
Table 91. AGC Biologics Latest Developments
Table 92. Rentschler Biopharma Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 93. Rentschler Biopharma Biopharmaceutical and Bio-CDMO Product Offered
Table 94. Rentschler Biopharma Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 95. Rentschler Biopharma Main Business
Table 96. Rentschler Biopharma Latest Developments
Table 97. KBI Biopharma Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 98. KBI Biopharma Biopharmaceutical and Bio-CDMO Product Offered
Table 99. KBI Biopharma Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 100. KBI Biopharma Main Business
Table 101. KBI Biopharma Latest Developments
Table 102. Siegfried Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 103. Siegfried Biopharmaceutical and Bio-CDMO Product Offered
Table 104. Siegfried Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 105. Siegfried Main Business
Table 106. Siegfried Latest Developments
Table 107. Aenova Group Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 108. Aenova Group Biopharmaceutical and Bio-CDMO Product Offered
Table 109. Aenova Group Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 110. Aenova Group Main Business
Table 111. Aenova Group Latest Developments
Table 112. GenScript Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 113. GenScript Biopharmaceutical and Bio-CDMO Product Offered
Table 114. GenScript Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 115. GenScript Main Business
Table 116. GenScript Latest Developments
Table 117. ProBioGen Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 118. ProBioGen Biopharmaceutical and Bio-CDMO Product Offered
Table 119. ProBioGen Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 120. ProBioGen Main Business
Table 121. ProBioGen Latest Developments
Table 122. Northway Biotech Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 123. Northway Biotech Biopharmaceutical and Bio-CDMO Product Offered
Table 124. Northway Biotech Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 125. Northway Biotech Main Business
Table 126. Northway Biotech Latest Developments
Table 127. 3P Biopharmaceuticals Details, Company Type, Biopharmaceutical and Bio-CDMO Area Served and Its Competitors
Table 128. 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Product Offered
Table 129. 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 130. 3P Biopharmaceuticals Main Business
Table 131. 3P Biopharmaceuticals Latest Developments

List of

Figure 1. Biopharmaceutical and Bio-CDMO Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Biopharmaceutical and Bio-CDMO Market Size Growth Rate 2019-2030 ($ millions)
Figure 6. Biopharmaceutical and Bio-CDMO Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Biopharmaceutical and Bio-CDMO Sales Market Share by Country/Region (2023)
Figure 8. Biopharmaceutical and Bio-CDMO Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Biopharmaceutical and Bio-CDMO Market Size Market Share by Type in 2023
Figure 10. Biopharmaceutical and Bio-CDMO in SMBs
Figure 11. Global Biopharmaceutical and Bio-CDMO Market: SMBs (2019-2024) & ($ millions)
Figure 12. Biopharmaceutical and Bio-CDMO in Large Companies
Figure 13. Global Biopharmaceutical and Bio-CDMO Market: Large Companies (2019-2024) & ($ millions)
Figure 14. Global Biopharmaceutical and Bio-CDMO Market Size Market Share by Application in 2023
Figure 15. Global Biopharmaceutical and Bio-CDMO Revenue Market Share by Player in 2023
Figure 16. Global Biopharmaceutical and Bio-CDMO Market Size Market Share by Region (2019-2024)
Figure 17. Americas Biopharmaceutical and Bio-CDMO Market Size 2019-2024 ($ millions)
Figure 18. APAC Biopharmaceutical and Bio-CDMO Market Size 2019-2024 ($ millions)
Figure 19. Europe Biopharmaceutical and Bio-CDMO Market Size 2019-2024 ($ millions)
Figure 20. Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size 2019-2024 ($ millions)
Figure 21. Americas Biopharmaceutical and Bio-CDMO Value Market Share by Country in 2023
Figure 22. United States Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 23. Canada Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 24. Mexico Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 25. Brazil Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 26. APAC Biopharmaceutical and Bio-CDMO Market Size Market Share by Region in 2023
Figure 27. APAC Biopharmaceutical and Bio-CDMO Market Size Market Share by Type (2019-2024)
Figure 28. APAC Biopharmaceutical and Bio-CDMO Market Size Market Share by Application (2019-2024)
Figure 29. China Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 30. Japan Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 31. South Korea Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 32. Southeast Asia Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 33. India Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 34. Australia Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 35. Europe Biopharmaceutical and Bio-CDMO Market Size Market Share by Country in 2023
Figure 36. Europe Biopharmaceutical and Bio-CDMO Market Size Market Share by Type (2019-2024)
Figure 37. Europe Biopharmaceutical and Bio-CDMO Market Size Market Share by Application (2019-2024)
Figure 38. Germany Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 39. France Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 40. UK Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 41. Italy Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 42. Russia Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 43. Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size Market Share by Region (2019-2024)
Figure 44. Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size Market Share by Type (2019-2024)
Figure 45. Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size Market Share by Application (2019-2024)
Figure 46. Egypt Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 47. South Africa Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 48. Israel Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 49. Turkey Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 50. GCC Countries Biopharmaceutical and Bio-CDMO Market Size Growth 2019-2024 ($ millions)
Figure 51. Americas Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 52. APAC Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 53. Europe Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 54. Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 55. United States Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 56. Canada Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 57. Mexico Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 58. Brazil Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 59. China Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 60. Japan Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 61. Korea Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 62. Southeast Asia Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 63. India Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 64. Australia Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 65. Germany Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 66. France Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 67. UK Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 68. Italy Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 69. Russia Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 70. Egypt Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 71. South Africa Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 72. Israel Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 73. Turkey Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 74. GCC Countries Biopharmaceutical and Bio-CDMO Market Size 2025-2030 ($ millions)
Figure 75. Global Biopharmaceutical and Bio-CDMO Market Size Market Share Forecast by Type (2025-2030)
Figure 76. Global Biopharmaceutical and Bio-CDMO Market Size Market Share Forecast by Application (2025-2030)

Related Reports

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted